全髋关节置换术中钽植入物的安全性研究
该研究对144例全髋关节置换术后患者进行平均4年随访,比较非钽初次置换、钽杯初次置换和钽壳翻修三组患者的血钽浓度及T细胞亚群。结果显示初次钽杯组血钽浓度与检测限相近,翻修钽组略高,但所有淋巴细胞亚群均在正常范围,未见假体松动,Harris髋关节评分良好至优秀。
要点
- 稳定钽杯初次全髋置换患者血钽浓度低,与检测限相近
- 翻修钽壳患者血钽浓度略高于初次置换组,但淋巴细胞亚群均正常
- 未见典型ALVAL的T细胞活化征象,无假体松动,髋关节功能良好
核心结论
- 稳定钽杯植入与低血钽浓度相关,未见典型ALVAL的T细胞活化征象。
研究设计与样本
- 回顾性比较研究,纳入144例全髋关节置换术后平均随访4年(范围0.5至8.9年)的患者,分为非钽初次置换组(n=30)、钽杯初次置换组(n=30)和钽壳翻修组(n=84),另以59名献血者作为免疫学参数对照。
主要发现
- 非钽初次置换组血钽中位浓度0.05 µg/L(95%CI 0.05至0.05 µg/L),钽杯初次置换组0.051 µg/L(95%CI 0.050至0.055 µg/L),钽壳翻修组0.091 µg/L(95%CI 0.083至0.112 µg/L),翻修组与两个初次置换组组间比较p<0.0001。
- 较高钽浓度与HLA-DR/CD8 T细胞浓度呈弱负相关(r=-0.22,95%CI -0.35至-0.05,p=0.01),与HLA-DR/CD4 T细胞浓度无相关性(r=-0.11,95%CI -0.27至0.06,p=0.24)。
- 所有淋巴细胞亚群数值均在正常范围内,无假体被判定为松动,Harris髋关节评分中位数良好至优秀。
关键数值与推荐
- 血钽浓度中位数:非钽初次置换组0.05 µg/L(95%CI 0.05至0.05 µg/L),钽杯初次置换组0.051 µg/L(95%CI 0.050至0.055 µg/L),钽壳翻修组0.091 µg/L(95%CI 0.083至0.112 µg/L)。
- 钽浓度与HLA-DR/CD8 T细胞弱负相关(r=-0.22,95%CI -0.35至-0.05,p=0.01),与HLA-DR/CD4 T细胞无相关(r=-0.11,95%CI -0.27至0.06,p=0.24)。
- 所有淋巴细胞亚群在正常范围,无假体松动,Harris髋关节评分中位数良好至优秀,证据等级治疗性III级。
临床怎么用
- 对于使用稳定钽杯的全髋关节置换患者,血钽浓度低且未见ALVAL相关T细胞活化征象,可支持其安全性评估。
- 翻修钽壳患者血钽浓度略高,随访中可关注免疫学参数,但本研究淋巴细胞亚群均在正常范围。
- 钽浓度与HLA-DR/CD8 T细胞的弱负相关临床意义尚不明确,不宜据此单独判断免疫异常。
局限性
- 本研究为单中心比较研究,证据等级为治疗性III级,随访时间平均4年,最长8.9年。
- 翻修钽壳组样本量较大(n=84),初次置换两组各30例,免疫学对照为59名献血者。
- 钽浓度与HLA-DR/CD8 T细胞仅呈弱负相关,相关性强度有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Tantalum implants have been used in >500,000 orthopaedic patients. Although the risks of metallosis and aseptic lymphocyte-dominated vasculitis-associated lesions (ALVAL) after total hip arthroplasty (THA) are being debated, we are not aware of any studies investigating the liberation of tantalum ions and their potential effects on the immune system. We evaluated whether tantalum concentrations are elevated after THA with acetabular tantalum implants and assessed potential alterations in T-cell subpopulations. METHODS: After a mean follow-up of 4 years (range, 0.5 to 8.9 years) of 144 patients who had undergone THA, blood samples were analyzed regarding blood tantalum concentrations, total white blood-cell counts, and lymphocyte subsets in 3 groups of patients: those treated with non-tantalum primary THA ("primary non-tantalum," n = 30), those treated with primary THA with a tantalum cup ("primary tantalum," n = 30), and those who underwent revision surgery with a tantalum shell ("revision tantalum," n = 84). Blood donors served as controls for immunological parameters (n = 59). Correlations between tantalum concentrations and human leukocyte antigen (HLA)-DR T cells were calculated, radiographic signs of implant loosening were assessed, and the Harris hip score (HHS) was used to evaluate hip function. RESULTS: The median tantalum concentration was similar to the detection limit both in the primary non-tantalum group (0.05 µg/L, 95% confidence interval [CI] = 0.05 to 0.05 µg/L) and in the primary tantalum group (0.051 µg/L, 95% CI = 0.050 to 0.055 µg/L), and it was 0.091 µg/L (95% CI = 0.083 to 0.112 µg/L) in the revision tantalum group (p < 0.0001 in the group-wise comparison with both primary non-tantalum and primary tantalum). We found a weak negative correlation of higher tantalum concentration with the concentration of HLA-DR/CD8 T cells (r = -0.22, 95% CI = -0.35 to -0.05, p = 0.01) but no correlation of tantalum concentration with the concentration of HLA-DR/CD4 T cells (r = -0.11, 95% CI = -0.27 to 0.06, p = 0.24). The values for all lymphocyte subgroups were within normal ranges. No implants were deemed loose. The median HHS was good to excellent. CONCLUSIONS: Exposure to stable tantalum cups is associated with low blood concentrations of tantalum. Signs of T-cell activation typical of ALVAL seem to be lacking. LEVEL OF EVIDENCE: Therapeutic Level III. See Instructions for Authors for a complete description of levels of evidence.
引用
- Brüggemann A, Mallmin H, Bengtsson M, et al. Safety of Use of Tantalum in Total Hip Arthroplasty. J Bone Joint Surg Am. 2020. PMID: 31895169. doi:10.2106/JBJS.19.00366
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。